News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|March 5, 2024

Unraveling Type 1 Diabetes: Differences Between Type 1 and Type 2

Robert Gabbay, MD, PhD, delineates key differences between type 1 and type 2 diabetes, including autoimmune antibodies, insulin resistance, and insulin deficiency.

Episodes in this series

Video 1 - "Unraveling Type 1 Diabetes: Differences Between Type 1 and Type 2"

EP. 1 Unraveling Type 1 Diabetes: Differences Between Type 1 and Type 2

Video 2 - "Early-stage Type 1 Diabetes and The Psychological Impact of Progressing to Stage 3"

EP. 2 Early-stage Type 1 Diabetes and The Psychological Impact of Progressing to Stage 3

Video 3 - "Identifying Risk to Enable Early Detection of Type 1 Diabetes "

EP. 3 Identifying Risk to Enable Early Detection of Type 1 Diabetes

Video 4 - "Challenges in Autoantibody Screening for Type 1 Diabetes"

EP. 4 Challenges in Autoantibody Screening for Type 1 Diabetes

Video 5 - "Strategies for Preventing Progression of Early-Stage Type 1 Diabetes"

EP. 5 Strategies for Preventing Progression of Early-Stage Type 1 Diabetes

Video 6 - "Optimal Approaches to Diagnostic Testing for Type 1 Diabetes Mellitus"

EP. 6 Optimal Approaches to Diagnostic Testing for Type 1 Diabetes Mellitus

Video 7 - "Harnessing Continuous Glucose Monitors for Type 1 Diabetes Management + Closing Words"

EP. 7 Harnessing Continuous Glucose Monitors for Type 1 Diabetes Management + Closing Words

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Dexamethasone Before R-CHOP in DLBCL With GI Involvement Can Limit Complications, Retain Efficacy

January 25th 2026

Doctor conducting liquid biopsy | Image Credit: syhin_stas - stock.adobe.com

ctDNA Positivity Associated With Worse Survival, Higher Recurrence Risk in Patients With NSCLC

ByBrooke McCormick

January 25th 2026

First-line anlotinib plus chemotherapy demonstrates favorable efficacy and manageable toxicity in advanced STS. | Image credit: @Aidman-Adobestock.jpeg

Anlotinib Plus Chemotherapy Shows Promising Results in Advanced Soft Tissue Sarcoma

BySabrina McCrear

January 23rd 2026

Mitzi Wasik, PharmD, MBA, BCPS, FAMCP, FCCP, executive director of the AMCP Foundation and senior vice president of Practice Strategy and Innovation at AMCP | Image credit: AMCP

RWD Is Transforming Mental Health, Neurology Managed Care: Mitzi Wasik, PharmD

ByRose McNulty,Mitzi Wasik, PharmD, MBA

January 22nd 2026

computer-generated lungs | Image Credit: Rasi - stock.adobe.com

Oral Nalbuphine Significantly Reduces Chronic Cough in IPF

BySabrina McCrear

January 22nd 2026

Latest CME

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

Trending on AJMC

Congress Unveils Massive Funding Bill to Avert Shutdown

ctDNA Positivity Associated With Worse Survival, Higher Recurrence Risk in Patients With NSCLC

Novel CLL Therapies Prompt New Treatment Considerations

Early Data Show Feasibility of in Vivo CAR T Therapy in Multiple Myeloma

Health Insurance CEOs Questioned by House Committee About Rising Costs in Health Care

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

© 2025 MJH Life Sciences^®

All rights reserved.